John Harlow

John Harlow is an accomplished executive in the biopharmaceutical industry, currently serving as Chief Commercial Officer at Esperion since November 2025, where leadership focuses on commercial operations and strategic partnerships for cardiovascular therapies. Previously, John held the role of Chief Commercial Officer at Melinta Therapeutics, contributing to the company's acquisition by CorMedix. With experience as Chief Commercial Officer at Baudax Bio and Executive Vice President, Commercial at Recro Pharma, John has successfully led product launches and navigated regulatory challenges. Earlier roles include significant leadership positions in sales and marketing at Endo Pharmaceuticals and Shionogi Inc., as well as marketing leadership within Pfizer and ALPHARMA. John holds a Bachelor's Degree in Biology from Lehigh University and an MBA in Pharmaceutical Management from Seton Hall University.